Pemvidutide: Trials and FDA Status
Pemvidutide is a glp-1/glucagon dual agonist. This page tracks its trials, sponsor and FDA status, with a dated source for each milestone.
Where it stands
- US status
- Investigational
- Phase
- Phase 3 (MASH)
- Sponsor
- Altimmune
- Expected FDA decision
- None announced
- no primary source states a date (checked 2 Oct 2026)
- Trial IDs (NCT)
- NCT05989711, NCT07795164
Reported results
- 2025IMPACT phase 2b (Lancet 2025): MASH resolution without fibrosis worsening at 24 weeks“MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the 1·2 mg pemvidutide group (difference of 38% [95% CI 21-56]; p<0·0001)”pubmed.ncbi.nlm.nih.gov
Company-reported figures are labelled as such. Results in a trial population may not match results elsewhere.
Milestones
- NCT07795164 (PERFORMA; Phase 3): primary completion (estimated)
- NCT07795164 (PERFORMA; Phase 3): first posted on ClinicalTrials.gov
- Altimmune reports initiation of the global PERFORMA phase 3 MASH trial
- NCT07795164 (PERFORMA; Phase 3): study start
- Altimmune reports FDA Breakthrough Therapy Designation for pemvidutide in MASH
- NCT05989711 (IMPACT; Phase 2): primary completion
- Published in Journal of hepatology (2025): Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
- Published in JHEP reports : innovation in hepatology (2025): Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.
- Published in Lancet (London, England) (2025): Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
- NCT05989711 (IMPACT; Phase 2): first posted on ClinicalTrials.gov
- NCT05989711 (IMPACT; Phase 2): study start
What the pemvidutide registry entries specify
IMPACT (NCT05989711) is titled as a phase 2, randomised, double-blind, placebo-controlled study of pemvidutide in non-cirrhotic NASH.[1]
IMPACT enrolled 212 participants.[1]
IMPACT is completed: it started 2023-07-27 and reached primary completion on 2025-11-25.[1]
The phase 3 trial (NCT07795164) is a randomised, double-blind, placebo-controlled study in noncirrhotic MASH, with clinical outcomes named in its title.[2]
It plans 1800 participants.[2]
It is recruiting: it started 2026-07-30 and primary completion is estimated for 2028-12.[2]
Primary endpoints and trial length
IMPACT's first primary outcome is MASH resolution with at least a 2-point NAS reduction and no worsening of fibrosis, assessed at 24 weeks.[1]
The phase 3 trial's primary outcome is listed as a clinical outcome event.[2]
From start to primary completion, IMPACT spans 122 weeks and the phase 3 trial 124 weeks.
Calculated from NCT05989711 start 2023-07-27, primary completion 2025-11-25, type ACTUAL; NCT07795164 start 2026-07-30, primary completion 2028-12, type ESTIMATED. Formula: weeks = round((primary completion date - start date) / 7 days); dates with no day are taken as the 15th
Published and sponsor-reported results
In IMPACT at 24 weeks, MASH resolution without fibrosis worsening occurred in 58% of 41 patients on 1.2 mg and 20% of 86 on placebo.[5]
Altimmune says FDA granted pemvidutide Breakthrough Therapy Designation based on 24-week data from the IMPACT trial.[7]
The company expects 52-week data from the global PERFORMA phase 3 trial in 2029.[7]
Common questions
Is pemvidutide in phase 3?
Yes. A phase 3 MASH trial started on 2026-07-30 and is recruiting.[2]
Sources
- 1IMPACT: IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (NCT05989711)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
- 2PERFORMA: Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH (NCT07795164)ClinicalTrials.gov (U.S. National Library of Medicine) · 2026clinicaltrials.govAccessed 2 Oct 2026
- 3Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.Journal of hepatology · 2025PMID 39002641Accessed 2 Oct 2026
- 4Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.JHEP reports : innovation in hepatology · 2025PMID 41113119Accessed 2 Oct 2026
- 5Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.Lancet (London, England) · 2025PMID 41237796Accessed 2 Oct 2026
- 6Altimmune reports FDA Breakthrough Therapy Designation for pemvidutide in MASHAltimmune (press release) · 2026sec.govAccessed 2 Oct 2026
- 7Altimmune reports initiation of the global PERFORMA phase 3 MASH trialAltimmune (press release) · 2026sec.govAccessed 2 Oct 2026
Found an error? Report a correction.